DIMERIX LTD
ASX: DXB (DIMERIX FPO [DXB])
Kemas kini terakhir: 7 jam lalu0.260
-0.01 (-3.70%)
| Penutupan Terdahulu | 0.270 |
| Jumlah Dagangan | 1,125,101 |
| Harga / Jualan (P/S) | 35.88 |
| Harga / Buku (P/B) | 24.45 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -4,556.12% |
| EPS Cair (TTM) | -0.040 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 116.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.18% |
| Nisbah Semasa (MRQ) | 4.77 |
| Aliran Tunai Operasi (OCF TTM) | -18.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.23 M |
| Pulangan Atas Aset (ROA TTM) | -79.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -524.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | DIMERIX FPO [DXB] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.33 |
|
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 23.75% |
| % Dimiliki oleh Institusi | 1.54% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |